G. Marx

G. S. Smith, N. Pavlakis, S. Gananadha, 2008, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

M. Stockler, W. Parulekar, M. Frydenberg, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Severe symptomatic hypocalcaemia following a single dose of denosumab

J. Mclachlan, G. Marx, M. Bridgman, 2013, The Medical journal of Australia.

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.

R. Bose, H. Rugo, D. Tripathy, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer.

N. Pavlakis, M. Khasraw, P. de Souza, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Pertuzumab study in the neoadjuvant setting for HER2‐positive nonmetastatic breast cancer in Australia (PeRSIA)

B. Kiely, P. Gibbs, G. Kichenadasse, 2022, International journal of cancer.

Pseudomyxoma peritonei: the ‘controversial’ disease

C. Steer, P. Harper, E. Galani, 2003, International Journal of Gynecologic Cancer.

Combined modality treatments in early non-small cell lung cancer.

P. Harper, G. Marx, 2002, Lung cancer.

Primary treatment of the prostate improves local palliation in men who ultimately develop castrate‐resistant prostate cancer

P. de Souza, H. Gurney, Manish I. Patel, 2013, BJU international.

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

M. Stockler, W. Parulekar, M. Frydenberg, 2019, The New England journal of medicine.

Elevated α-foetoprotein and hepatic metastases—it’s not always what it seems!

D. Goldstein, A. Boyce, G. Marx, 2002 .

Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme

N. Pavlakis, H. Wheeler, R. Cook, 2001, Journal of Neuro-Oncology.

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer

M. Stockler, L. Horvath, A. Swarbrick, 2017, British Journal of Cancer.

Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase

M. Stockler, P. Meikle, L. Horvath, 2021, EBioMedicine.

A distinct plasma lipid signature associated with poor prognosis in castration‐resistant prostate cancer

M. Stockler, P. Meikle, P. Mundra, 2017, International Journal of Cancer.

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.

A. Drilon, C. Rudin, M. Kris, 2016, Lung cancer.

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer

M. Stockler, M. Chatfield, S. Clark, 2014, British Journal of Cancer.

Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time.

F. Saad, K. Miller, B. Tombal, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid

L. Fallowfield, C. Cleeland, D. Patrick, 2013, Supportive Care in Cancer.

Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.

M. Stockler, W. Parulekar, M. Frydenberg, 2021, European urology.

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer

M. Stockler, M. Chatfield, N. Pavlakis, 2015, British Journal of Cancer.

Vaginal CO2 laser for the treatment of vulvovaginal atrophy in women with breast cancer: LAAVA pilot study

M. Tio, G. Marx, A. Pearson, 2019, Breast Cancer Research and Treatment.

Factors associated with the development and severity of oxaliplatin‐induced peripheral neuropathy: a systematic review

G. Marx, Jeremy N. Pulvers, Jeremy N. Pulvers, 2017, Asia-Pacific journal of clinical oncology.

Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.

M. Stockler, N. Pavlakis, R. Sutherland, 2009, Cancer research.

Drug reaction with eosinophilia and systemic symptoms in metastatic basal cell carcinoma treated with vismodegib

K. Baumgart, P. Fernández-Peñas, M. Arasaratnam, 2017, The Australasian journal of dermatology.

Circulating microRNAs associated with docetaxel-resistant castration resistant prostate cancer.

M. Stockler, N. Pavlakis, S. Clark, 2014 .

The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine.

N. Pavlakis, S. Clarke, S. Kao, 2012, Lung cancer.

Modafinil for fatigue associated with docetaxel-based chemotherapy: A randomized controlled trial.

P. Craft, P. de Souza, E. Hovey, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P10. Effect of GFR methodology on carboplatin dosing

D. Bailey, C. Steer, G. Blake, 2002 .

The impact and indications for Oncotype DX on adjuvant treatment recommendations when third‐party funding is unavailable

B. Kiely, G. Mann, Y. Antill, 2018, Asia-Pacific journal of clinical oncology.

Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

R. Bose, H. Rugo, C. Singer, 2022, Breast.

Anti‐angiogenic therapy for lung cancer

N. Pavlakis, M. Khasraw, Christopher W. Lee, 2009 .

Bringing diarrhea under CONTROL: dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer

D. Tripathy, M. Trudeau, A. Brufsky, 2021 .

Efficacy of management strategies for aromatase inhibitor‐induced arthralgia in breast cancer patients: a systematic review

Susan Mee, G. Marx, Nicole Nahm, 2018, Asia-Pacific journal of clinical oncology.

Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics.

F. Saad, K. Miller, B. Tombal, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Geriatric assessment of older patients with cancer in Australia--a multicentre audit.

M. Tattersall, C. Steer, L. Mileshkin, 2015, Journal of geriatric oncology.

Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor‐positive breast cancer

Bob T. Li, P. Mccloud, A. Tan, 2018, Asia-Pacific journal of clinical oncology.

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

V. Gebski, P. Gibbs, F. Lammert, 2017, The Lancet. Oncology.

E. Hovey, A. Lloyd, P. Parente, 2017, Supportive Care in Cancer.

Cisplatin-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH) with life-threatening hyponatraemia

A. Tan, G. Marx, 2018, BMJ Case Reports.

Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics.

F. Saad, K. Miller, B. Tombal, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.

M. Stockler, W. Parulekar, M. Frydenberg, 2023, The Lancet. Oncology.

CHEMOTHERAPY IN THE ELDERLY

M. Khasraw, G. Marx, 2008 .

FORUM C HEMOTHERAPY IN THE ELDERLY

M. Khasraw, G. Marx, 2022 .

Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.

R. Simes, L. Chantrill, D. Goldstein, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN: Asian subpopulation.

E. Small, P. Mainwaring, T. Kwon, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

M. Stockler, L. Horvath, I. Davis, 2019, Annals of Oncology.

Outpatient treatment with subcutaneous interleukin‐2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience

D. Goldstein, J. Taylor, G. Marx, 2005, Internal medicine journal.

The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting

J. Boyages, S. Edirimanne, T. M. Hughes, 2022, The breast journal.

Pathological outcomes of HER2‐positive non‐metastatic breast cancer patients treated with neoadjuvant dual anti‐HER2 therapy and taxane: An Australian experience

T. M. Hughes, N. Ngui, J. Choi, 2020, Asia-Pacific journal of clinical oncology.

POOR UPTAKE OF INFLUENZA VACCINATIONS IN PATIENTS RECEIVING CYTOTOXIC CHEMOTHERAPY

C. Steer, A. Ring, P. Ellis, 2003, International journal of clinical practice.

Reply to the letter “Limitations of bedside estimates of renal function”, by M. J. Dooley and S. G. Poole (doi:10.1093/annonc/mdi173)

C. Steer, P. Harper, G. Marx, 2005 .

Demonstrating the feasibility of collecting secondary, de‐identified data on Australian patients receiving treatment as part of a Medicine Access Programme

P. Gibbs, H. Wong, B. Tran, 2020, Internal medicine journal.

99 The impact of bone metastases on pain: Results from a phase III denosumab study in men with nonmetastatic castration-resistant prostate cancer

F. Saad, L. Fallowfield, C. Cleeland, 2013 .

Phase I study of docetaxel plus ifosfamide in patients with advanced cancer

S. Ackland, K. Hall, C. Lewis, 2002, British Journal of Cancer.

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

D. Amadori, S. Fosså, A. Haese*, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

D. Amadori, S. Fosså, C. Parker, 2011 .

Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).

E. Basch, H. Scher, J. Bono, 2015 .

The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]

P. Gibbs, S. Clarke, M. Molloy, 2020, PloS one.

Second‐line therapy for castrate‐resistant prostate cancer: A literature review

E. Hovey, G. Marx, S. Kao, 2011, Asia-Pacific journal of clinical oncology.

Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy

P. Craft, P. de Souza, E. Hovey, 2014, Supportive Care in Cancer.

A phase I and II trial of epirubicin, cisplatin, 24‐hour infusion 5 fluorouracil and sodium folinate in patients with advanced esophagogastric carcinomas

C. Steer, C. Karapetis, D. Yip, 2010, Asia-Pacific journal of clinical oncology.

Non-platinum gemcitabine combinations in non-small cell lung cancer.

P. Harper, G. Marx, 2002, Lung cancer.

Daily life as an Australian medical oncologist.

G. Marx, D. Adams, 2010, Journal of Oncology Practice.

Geriatric assessment of older patients with cancer in Australia--a multicentre audit.

M. Tattersall, C. Steer, L. Mileshkin, 2015, Journal of geriatric oncology.

Abstract PD10-02: A randomised phase II trial of single fraction or multi-fraction SABR (stereotactic ablative body radiotherapy) with atezolizumab in patients with advanced triple negative breast cancer (AZTEC trial)

S. Loi, P. Savas, S. Siva, 2022, Cancer Research.

The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).

M. Stockler, M. Chatfield, N. Pavlakis, 2013 .